Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141


Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC).

Vasarainen H, Malmi H, Määttänen L, Ruutu M, Tammela T, Taari K, Rannikko A, Auvinen A.

Acta Oncol. 2013 Nov;52(8):1615-21. doi: 10.3109/0284186X.2013.802837. Epub 2013 Jun 20.


Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial.

Vasarainen H, Lokman U, Ruutu M, Taari K, Rannikko A.

BJU Int. 2012 Jun;109(11):1614-9. doi: 10.1111/j.1464-410X.2011.10677.x. Epub 2011 Nov 1.


Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial.

Malmi H, Ruutu M, Määttänen L, Stenman UH, Juusela H, Tammela TL, Auvinen A.

BJU Int. 2010 Aug;106(4):472-7. doi: 10.1111/j.1464-410X.2010.09165.x. Epub 2010 Feb 22.


The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.

Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.

Eur Urol. 2008 Sep;54(3):581-8. doi: 10.1016/j.eururo.2008.03.104. Epub 2008 Apr 8.


Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.


Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.

Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1654-60. doi: 10.1111/j.1464-410X.2012.11481.x. Epub 2012 Oct 8.


Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.


Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.


Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.

Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Lévesque J, Brousseau G, Bélanger A, Labrie F.

Prostate. 2000 Sep 15;45(1):19-35.


Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.


[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.


Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, Lane JA, Peters TJ.

BJU Int. 2006 Oct;98(4):777-82.


Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).

Roobol MJ, Kirkels WJ, Schröder FH.

BJU Int. 2003 Dec;92 Suppl 2:48-54.


Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group.

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.


A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.

Eur Urol. 2013 Apr;63(4):627-33. doi: 10.1016/j.eururo.2012.07.029. Epub 2012 Jul 20.


Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).

Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.

J Med Assoc Thai. 2006 Jan;89(1):37-42.


The Finnish prostate cancer screening trial: analyses on the screening failures.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

Int J Cancer. 2015 May 15;136(10):2437-43. doi: 10.1002/ijc.29300. Epub 2014 Nov 10.


Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.

Loeb S, Zhu X, Schroder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1678-83. doi: 10.1111/j.1464-410X.2012.11367.x. Epub 2012 Sep 21.


[Screening for early detection of prostate cancer (first experience in Israel)].

Neheman A, Shotland Y, Metz Y, Stein A.

Harefuah. 2001 Jan;140(1):4-10, 88, 87. Hebrew.


Supplemental Content

Support Center